Recombinant Human CD155/PVR Fc Chimera Protein, CF Summary
Accession # NP_006496
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human CD155/PVR Fc Chimera (Catalog # 9174-CD) is immobilized at 1 µg/mL, Recombinant Human CD96 v2 Fc Chimera (Catalog # 9556-CD) binds with an ED50 of 30-150 ng/mL.
CD155, also known as PVR (poliovirus receptor), Necl-5 (nectin-like molecule-5) and, in rodents, TAGE4 (tumor-associated glycoprotein E4), is a 70 kDa type I transmembrane glycoprotein in the nectin-related family of adhesion proteins within the immunoglobulin superfamily (1, 2). CD155 binds other molecules including Vitronectin, Nectin-3, DNAM-1/CD226, CD96, and TIGIT but does not bind homotypically (3). Mature human CD155 consists of a 323 amino acid (aa) extracellular domain (ECD) with one N-terminal V-type and two C2-type Ig-like domains, a 24 aa transmembrane segment, and a 50 aa cytoplasmic tail. Within the ECD, human CD155 shares 45% aa sequence identity with mouse and rat CD155, and 52% with human Nectin-2. The V-type domain of CD155 mediates all binding, including to polio virus (1), and alternative splicing within this domain in humans can modulate ligand binding (4). Human CD155 can also be spliced to generate secreted isoforms (5). CD155 is up-regulated on endothelial cells by IFN-gamma and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin (1, 2, 6-9). It is preferentially expressed on Th17 cells compared to Th2 cells (10), and its activation promotes the development of Th1 responses (11). On migrating cells, CD155 is concentrated at the leading edge, where it binds basement membrane Vitronectin, recruits Nectin-3-expressing cells, and cooperates with PDGF and Integrin alpha v beta 3 to promote cell migration (1, 3, 12). Enhanced CD155 expression in tumor cells contributes to loss of contact inhibition and increased migration but also allows tumor cell recognition and killing by DNAM-1 or CD96 expressing NK cells (1, 7, 13). Binding of monocyte DNAM-1 to endothelial cell CD155 promotes transendothelial migration (8). The expression of CD155 on mouse CD8+ thymocytes prevents their premature exit from the thymus (14). Within intestinal Peyer's patches, follicular dendritic cell CD155 activates follicular helper T cells via DNAM-1 or CD96 binding (7-9, 15). CD155 also binds the inhibitory ligand TIGIT on NK and some mature T cells, antagonizing DNAM-1 effects (7, 15, 16).
- Mandai, K. et al. (2015) Curr. Top. Dev. Biol. 112:197.
- Mendelsohn, C.L. et al. (1989) Cell 56:855.
- Sato, T. et al. (2004) Genes to Cells 9:791.
- Meyer, D. et al. (2009) J. Biol. Chem. 284:2235.
- Koike, S. et al. (1990) EMBO J. 9:3217.
- Escalante, N.K. et al. (2011) Arterioscler. Thromb. Vasc. Biol. 31:1177.
- Xu, Z. and B. Jin (2010) Cell. Mol. Immunol. 7:11.
- Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
- Maier, M.K. et al. (2007) Eur. J. Immunol. 37 :2214.
- Lozano, E. et al. (2013) J. Immunol. 191:3673.
- Yamashita-Kanemaru, Y. et al. (2015) J. Immunol. 194:5644.
- Mueller, S. and E. Wimmer (2003) J. Biol. Chem. 278:31251.
- Chan, C.J. et al. (2010) J. Immunol. 184:902.
- Qui, Q. et al. (2010) J. Immunol. 184:1681.
- Seth, S. et al. (2009) Eur. J. Immunol. 39:3160.
- Stanietsky, N. et al. (2009) Proc. Natl. Acad. Sci. USA 106:17858.
Citations for Recombinant Human CD155/PVR Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
Authors: J Preillon, J Cuende, V Rabolli, L Garnero, M Mercier, N Wald, A Pappalardo, S Denies, D Jamart, AC Michaux, R Pirson, V Pitard, M Bagot, S Prasad, E Houthuys, M Brouwer, R Marillier, F Lambolez, JR Marchante, F Nyawouame, MJ Carter, V Baron-Bodo, A Marie-Card, M Cragg, J Déchanet-M, G Driessens, C Hoofd
Molecular Cancer Therapeutics, 2020;0(0):.
Sample Types: Whole Cells
Applications: Cell Culture
TIGIT signaling restores suppressor function of Th1 Tregs
Authors: LE Lucca, PP Axisa, ER Singer, NM Nolan, M Dominguez-, DA Hafler
JCI Insight, 2019;4(3):.
Sample Types: Whole Cells
Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery
Authors: JK Fierle, J Abram-Sali, M Brioschi, M deTiani, G Coukos, SM Dunn
Sci Rep, 2019;9(1):12815.
Sample Types: Recombinant Protein
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human CD155/PVR Fc Chimera Protein, CF
Average Rating: 4 (Based on 1 Review)
Have you used Recombinant Human CD155/PVR Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image